* Chiron Corp., of Emeryville, Calif., paid about $113 million topurchase a 49 percent interest in the vaccine business ofBehringwerke AG, of Marburg, Germany. The deal, announcedearlier this year, also includes formation of a joint venture betweenChiron and Behringwerke, a subsidiary of Frankfurt, Germany-basedHoechst AG, to be called Chiron Behring GmbH & Co. (SeeBioWorld Today, Feb. 21, 1996, p. 1.)

* Genzyme Corp., of Cambridge, Mass., completed its $250 millionacquisition of Deknatel Snowden Pencer Inc., of Fall River, Mass.Genzyme took over the privately held surgical instruments companyto help boost introduction of the biotechnology company's post-operative anti-adhesion devices. (See BioWorld Today, May 29,1996, p. 1.)

* MedImmune Inc., of Gaithersburg, Md., sold $60 million worth of7 percent convertible subordinated notes, which are due in sevenyears. The notes can be converted to common stock at $19.68.MedImmune proposed the financing in June 1996. (See BioWorldToday, June 21, 1996, p. 1.)

* Sugen Inc., of Redwood City, Calif., entered a drug discoverycollaboration with the Chinese Academy of Sciences. Sugen willhave access to plant and microbial collections of the academy'sInstitutes of Botany and Microbiology for use in discoveringcompounds that inhibit signal transduction in cells. Financial termswere not disclosed.

(c) 1997 American Health Consultants. All rights reserved.